Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
InChi: InChI=1S/C27H33N5O2/c1-27(2
Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation
Oxacarbazepine
30)/b27-17+
MK-3697 p-016 InChi: InChI=1S/C27H33N5O2/c1-27(2MK 3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists . MK 3697 is also the third insomnia drug, currently being developed by Merck. MK 3697 has Ki = 0. 95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK 3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species. Product information CAS Number:
US$ 125.00
US$ 146.00
US$ 111.00
US$ 516.50
US$ 158.00
US$ 169.00
US$ 138.00
US$ 187.00
US$ 138.00
US$ 147.00
US$ 106.50